Allergan buys assets of gene therapy company RetroSense for $60m : digitallook

As it stated in digitallook

Allergan buys assets of gene therapy company RetroSense for $60m

Allergan buys assets of gene therapy company RetroSense for $60m

Michele Maatouk | Sharecast | 06 Sep, 2016 13:32 - Updated: 13:40 | | |Allergan Inc. 240.22-0.00% -0.00 Max: 240.22Min: 240.22 Volume: 0MM 200 : n/a 21:26 12/06/15 S&P 500 2,182.580.12% 2.60 Max: 2,184.13Min: 2,175.10 Volume: 0MM 200 : n/a 17:40 06/09/16Pharmaceutical group Allergan has acquired almost all the assets of privately-held biotechnology company RetroSense for $60m upfront.Under the terms of the deal, Allergan has also agreed to potential regulatory and commercialisation milestone payments related to its lead development programme, RST-001, which is a novel gene therapy for the potential treatment of retinitis pigmentosa (RP).Allergan's chief executive officer and president Brent Saunders said: "The acquisition of RetroSense and its RST-001 program builds on Allergan's deep commitment to eye care, and our focus on investing in game-changing innovation for retinal conditions, including retinitis pigmentosa, where patients desperately need treatment options."RP is a group of rare, inherited genetic disorders characterised by progressive peripheral vision loss and night vision difficulties followed by eventual central vision loss and blindness in many cases.


in like manner reuters

BRIEF-Allergan acquires gene therapy company Retrosense Therapeutics

BRIEF-Allergan acquires gene therapy company Retrosense Therapeutics

Sept 6 Allergan Plc :* Allergan Acquires Gene Therapy Company Retrosense Therapeutics Adding First-In-Class technology to company's innovative eye care pipeline* Says under terms of transaction, Allergan has paid Retrosense a $60 million upfront payment* Says also has agreed to potential regulatory and commercialization milestone payments related to rst-001* Says acquired substantially all of assets of Retrosense in an all-cash transaction Source text for Eikon: Further company coverage:


in like manner fiercebiotech

Allergan snaps up gene therapy startup to restore vision in rare disease patients

Allergan snaps up gene therapy startup to restore vision in rare disease patients

Allergan ($AGN) has bought gene therapy startup RetroSense Therapeutics to gain an early clinical candidate to treat the rare vision disorder retinitis pigmentosa (RP).The aim is to use this optogenetic approach to actually reverse vision deterioration in these patients.The biopharma paid $60 million up front, with additional, undisclosed regulatory and commercialization milestones tied to the lead program, RST-001 to treat RP.